303 related articles for article (PubMed ID: 31766196)
1. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.
Aurilio G; Piva F; Santoni M; Cimadamore A; Sorgentoni G; Lopez-Beltran A; Cheng L; Battelli N; Nolè F; Montironi R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766196
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
4. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.
Turco F; Tucci M; Di Stefano RF; Samuelly A; Bungaro M; Audisio M; Pisano C; Di Maio M; Scagliotti GV; Buttigliero C
Endocr Relat Cancer; 2021 Jun; 28(7):R207-R216. PubMed ID: 33949971
[TBL] [Abstract][Full Text] [Related]
6. The Role of Metabolic Factors in Renal Cancers.
Rysz J; Franczyk B; Ławiński J; Olszewski R; Gluba-Brzózka A
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33008076
[TBL] [Abstract][Full Text] [Related]
7. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
9. Obesity and renal cell carcinoma risk by histologic subtype: A nested case-control study and meta-analysis.
Callahan CL; Hofmann JN; Corley DA; Zhao WK; Shuch B; Chow WH; Purdue MP
Cancer Epidemiol; 2018 Oct; 56():31-37. PubMed ID: 30029068
[TBL] [Abstract][Full Text] [Related]
10. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
12. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
Zibelman M; Plimack ER
J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series.
Gu W; Zhu Y; Wang H; Zhang H; Shi G; Liu X; Ye D
PLoS One; 2015; 10(2):e0118022. PubMed ID: 25668688
[TBL] [Abstract][Full Text] [Related]
14. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
[TBL] [Abstract][Full Text] [Related]
15. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
17. Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer.
Blute ML; Zorn K; Grimes M; Shi F; Downs TM; Jarrard DF; Best SL; Richards K; Nakada SY; Abel EJ
BJU Int; 2016 Sep; 118(3):399-407. PubMed ID: 26589741
[TBL] [Abstract][Full Text] [Related]
18. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
19. Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases.
Qi N; Chen Y; Gong K; Li H
World J Surg Oncol; 2018 Jan; 16(1):16. PubMed ID: 29370814
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma: current status and emerging therapies.
Nelson EC; Evans CP; Lara PN
Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
